TP53 and ovarian serous adenocarcinoma: For the treatment of high-grade serous ovarian cancer (HGSOC), which has TP53 gene mutations with 96–100% frequency, PRIMA-1MET, a p53 reactivator that modifies amino acids in the mutant p53 core domain, was combined with SHetA2.